A new type of immunotherapy, developed by UCL researchers, has shown promising preclinical results against a bone cancer called osteosarcoma, as part of a study in mice.
Satellos expects to begin first-in-human clinical trials mid-year for SAT-3247, an oral small molecule drug candidate in development as a novel regenerative medicine approach to treating DMD
.
Satellos Bioscience Inc. announced the formation of a Clinical Advisory Board comprised of distinguished clinical research leaders and experts in drug development in genetic muscle disorders,.
BOSTON - Rhythm Pharmaceuticals, Inc. , a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases,.
IMCIVREE expected to be funded and available for use in England and Wales within three months through the National Health Service in specialist centresBOSTON, May 22, 2024 Rhythm.